Last reviewed · How we verify
Phase I Study of OSI-7904L in Combination With Cisplatin in Patients With Advanced Solid Tumors
This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.
Details
| Lead sponsor | OSI Pharmaceuticals |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 25 |
| Start date | 2003-06 |
| Completion | 2004-12 |
Conditions
- Advanced Solid Tumors
Interventions
- OSI-7904L
- Cisplatin
Countries
United States